Alpha Tau Medical Ltd DRTS 深 滬
交易中 04-06 10:58:33 美东时间
7.12
+0.200
+2.89%
華盛通- 最 高7.17
- 今 開7.00
- 成交量 8.82万股
- 最 低 6.86
- 昨 收 6.92
- 總市值 6.27亿
- 52周最高 8.60
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 2.50
- 委 比 7.83%
- 總股本 8800.97万
- 歷史最高 20.65
- 量 比 2.37
- 振 幅 4.48%
- 歷史最低 1.75
- 每 手 1
- 風險率 1.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
Alpha Tau Medical Ltd announced that an abstract presenting results of two clinical trials in pancreatic cancer patients in Jerusalem has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. The presentation, led by Dr. Harold Jacob, will discuss the feasibility, safety, and tumor control data from studies conducted at Hadassah Medical Center. Uzi Sofer, CEO of Alpha Tau, highlighted the significance of this milestone, not...
03-31 13:15
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Citigroup Maintains Buy on Alpha Tau Medical, Raises Price Target to $9
Citigroup analyst Yigal Nochomovitz maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $7 to $9.
03-11 23:53
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Alpha Tau Medical Q4 EPS $(0.14) Misses $(0.12) Estimate
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 13.82 percent. This is a 7.69 percent decrease over losses of $(0.13) per share
03-10 04:06
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Piper Sandler Downgrades Alpha Tau Medical to Neutral, Maintains Price Target to $5
Piper Sandler analyst Jason Bednar downgrades Alpha Tau Medical (NASDAQ:DRTS) from Overweight to Neutral and maintains the price target from $5 to $5.
03-04 18:34
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Alpha Tau Medical Ltd has received Japan's Shonin marketing approval for its Alpha DaRT therapy, targeting unresectable locally advanced or recurrent head and neck cancer. This marks the first approval outside Israel and the most stringent pathway for medical devices in Japan. A post-market surveillance study involving 66 patients will assess real-world safety and efficacy. Alpha Tau and HekaBio aim to generate clinical data and explore reimburse...
02-24 14:00
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
Alpha Tau Medical Ltd.在2025年取得显著进展，并计划在2026年继续推进其Alpha DaRT放射性疗法的临床试验和商业化准备。公司专注于治疗多种癌症，包括复发性皮肤鳞状细胞癌（通过ReSTART试验）、胰腺癌（IMPACT研究）、脑瘤（复发性胶质母细胞瘤的可行性研究）以及前列腺癌。Alpha Tau正在美国、欧洲、日本和以色列开展多项试验，并计划扩大产能以支持未来的商业化。此外，公司已申请其技术在日本的监管批准，并继续致力于专利保护和知识产权维护。公司现金流稳定，支持其当前的运营和未来发展。
01-29 14:00
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 200 points ...
01-14 22:52
